Abstract
Background Antibody-mediated rejection (AMR) remains the major risk factor for allograft loss across all solid organ transplantation. Unfortunately, its diagnosis relies on biopsy, an invasive gold standard that often sample unaffected allograft tissue leading to missed diagnosis. Plasma donor-derived cell-free DNA (dd-cfDNA) is noninvasive biomarker that has high sensitivity but low specificity for AMR diagnosis. This proof-of-concept study assessed the utility of cell-free chromatin immunoprecipitation (cfChIP) as a surrogate for gene expression to detect cardiac AMR and the associated pathobiology.
Methods The discovery GRAfT multicenter cohort of heart transplant patients (NCT02423070) identified AMR, acute cellular rejection (ACR), and stable controls based on biopsy and dd-cfDNA results. Plasma cfChIP-sequencing was performed to identify peaks, associated genes and pathobiological pathways. Plasma from an external cohort (GTD, NCT01985412) was also analyzed to verify pathways identified. Digital droplet PCR (ddPCR) assays targeting differential regions were constructed to test the diagnostic performance of cfDNA to detect AMR/ACR from stable controls (rejection-specific assays) or AMR from ACR (AMR-specific assays).
Results The cohort included 21 AMR, 28 ACR, and 45 stable controls from GRAfT and GTD, and 23 healthy controls. cfChIP detected expected active genes, including housekeeping genes and gene targets of transplant immunosuppressive drugs but not inactive genes. Unsupervised clustering of the discovery GRAfT cohort assigned 95% of samples correctly as AMR, ACR or stable control. Differential analysis identified pathobiological pathways of AMR such as neutrophil degranulation and complement activation. The pathways were consistent in GTD samples. Rejection-specific assays detected AMR/ACR from controls with AUC of 0.78 - 0.95. AMR-specific assays detected AMR from ACR with AUC of 0.71 - 0.85, sensitivities of 0.73 - 0.94 and specificities of 0.73 - 0.80.
Conclusion This study provides valuable preliminary data supporting the use of cfChIP to detect AMR and the associated pathobiological pathways.
Competing Interest Statement
Dr. Hannah Valatine is Board of Director for CareDx Inc.
Clinical Trial
ClinicalTrials.gov NCT00001846
Funding Statement
This research was supported by funding from the Cystic Fibrosis Foundation (AGBORE20QI0), the National Institutes of Health Distinguished Scholar Program, and the National Heart, Lung, and Blood Institute, Division of Intramural Research (S.A.-E.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review boards of the NIH and participating centers.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, S.A.E., upon reasonable request.
Abbreviations
- ACR
- acute cellular rejection
- AMR
- antibody-mediated rejection
- AUC
- area under the curve
- ddcfDNA
- donor-derived cell-free DNA
- ddPCR
- Digital droplet PCR
- cfChIP
- cell-free chromatin immunoprecipitation
- ChIP
- Chromatin immunoprecipitation
- GPCR
- G protein-coupled receptors
- HC
- healthy controls
- IQR
- interquartile ranges
- PPI
- Protein-protein interaction
- RPGC
- reads per genomic content
- SC
- stable controls
- TMM
- trimmed mean of M-values
- UMAP
- Uniform Manifold Approximation and Projection
